Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanatinostat mass balance and bioavailability in advanced cancer
NCT06302140Phase 1Terminated
- Sponsor
- Viracta Therapeutics, Inc.
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nanatinostat in cancer (4 arms), sponsored by Viracta Therapeutics, Inc. Primary endpoints: Amount of radioactivity in excreta at 8 weeks, Area under the plasma concentration versus time curve at 8 weeks and 4 more. Started Feb 2024; status: terminated.
02
Drugs
nanatinostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06302140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302140.